About this Journal Submit a Manuscript Table of Contents 
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 831282, 8 pages
doi:10.1155/2012/831282
Research Article

Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates

Ai-Hsiang Chou,1 Chia-Chyi Liu,1 Jui-Yuan Chang,1 Shu-Pei Lien,1 Meng-Shin Guo,1 Hau-Pong Tasi,1 Kuang-Nan Hsiao,1 Shih-Jen Liu,1 Charles Sia,1 Suh-Chin Wu,1,2 Min-Shi Lee,1 Chia-Hsin Hsiao,1 Jen-Ren Wang,3 Yen-Hung Chow,1 and Pele Chong1,4

1Vaccine R&D Center, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan Township, Miaoli County, Taiwan
2Institute of Biotechnology, National Tsing Hua University, Hsinchu, Taiwan
3Department of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan, Taiwan
4Graduate Institute of Immunology, China Medical University, Taichung, Taiwan

Received 18 February 2012; Revised 31 July 2012; Accepted 5 August 2012

Academic Editor: Sazaly Abu Bakar

Copyright © 2012 Ai-Hsiang Chou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Ho, E. R. Chen, K. H. Hsu et al., “An epidemic of enterovirus 71 infection in Taiwan,” The New England Journal of Medicine, vol. 341, no. 13, pp. 929–935, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. P. C. McMinn, “An overview of the evolution of enterovirus 71 and its clinical and public health significance,” FEMS Microbiology Reviews, vol. 26, no. 1, pp. 91–107, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Xu, Y. Qian, S. Wang et al., “EV71: an emerging infectious disease vaccine target in the Far East?” Vaccine, vol. 28, no. 20, pp. 3516–3521, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. M. S. Lee and L. Y. Chang, “Development of enterovirus 71 vaccines,” Expert Review of Vaccines, vol. 9, no. 2, pp. 149–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Solomon, P. Lewthwaite, D. Perera, M. J. Cardosa, P. McMinn, and M. H. Ooi, “Virology, epidemiology, pathogenesis, and control of enterovirus 71,” The Lancet Infectious Diseases, vol. 10, no. 11, pp. 778–790, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. L. Huang, M. S. Ho, and M. S. Lee, “Enterovirus 71 vaccine: when will it be available?” Journal of the Formosan Medical Association, vol. 110, pp. 425–427, 2011.
  7. N. J. Schmidt, E. H. Lennette, and H. H. Ho, “An apparently new enterovirus isolated from patients with disease of the central nervous system,” Journal of Infectious Diseases, vol. 129, no. 3, pp. 304–309, 1974. View at Scopus
  8. Y. C. Chung, M. S. Ho, J. C. Wu et al., “Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge,” Vaccine, vol. 26, no. 15, pp. 1855–1862, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. B. A. Brown and M. A. Pallansch, “Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus,” Virus Research, vol. 39, no. 2-3, pp. 195–205, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Bible, M. Iturriza-Gomara, B. Megson et al., “Molecular epidemiology of human enterovirus 71 in the United Kingdom from 1998 to 2006,” Journal of Clinical Microbiology, vol. 46, no. 10, pp. 3192–3200, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. Y. F. Chan, I. C. Sam, and S. C. Abubakar, “Phylogenetic designation of enterovirus 71 genotypes and subgenotypes using complete genome sequences,” Infection, Genetics and Evolution, vol. 10, no. 3, pp. 404–412, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. W. Huang, Y. W. Hsu, D. J. Smith et al., “Reemergence of enterovirus 71 in 2008 in Taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008,” Journal of Clinical Microbiology, vol. 47, no. 11, pp. 3653–3662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Diamanti, B. Ibrahimi, F. Tafaj et al., “Surveillance of suspected poliomyelitis in Albania, 1980-1995: suggestion of increased risk of vaccine associated poliomyelitis,” Vaccine, vol. 16, no. 9-10, pp. 940–948, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. R. C. Chan, D. J. Penney, D. Little, I. W. Carter, J. A. Roberts, and W. D. Rawlinson, “Hepatitis and death following vaccination with 17D-204 yellow fever vaccine,” The Lancet, vol. 358, no. 9276, pp. 121–122, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. C. N. Wu, Y. C. Lin, C. Fann, N. S. Liao, S. R. Shih, and M. S. Ho, “Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus,” Vaccine, vol. 20, no. 5-6, pp. 895–904, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. C. C. Liu, W. C. Lian, M. Butler, and S. C. Wu, “High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture,” Vaccine, vol. 25, no. 1, pp. 19–24, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. W. S. Tung, S. A. Bakar, Z. Sekawi, and R. Rosli, “DNA vaccine constructs against enterovirus 71 elicit immune response in mice,” Genetic Vaccines and Therapy, vol. 5, article 6, 2007.
  18. J. Y. Chang, C. P. Chang, H. H. P. Tsai, et al., “Selection and characterization of vaccine strain for Enterovirus 71 vaccine development,” Vaccine, vol. 30, no. 4, pp. 703–711, 2012.
  19. C. C. Liu, H. W. Chang, G. Yang, et al., “Development of a quantitative enzyme linked immunosorbent assay for monitoring the EV71 vaccine manufacturing process,” Journal of Virological Methods, vol. 176, no. 1-2, pp. 60–68, 2011. View at Publisher · View at Google Scholar
  20. C. C. Liu, A. H. Chou, S. P. Lien et al., “Identification and characterization of a cross-neutralization epitope of Enterovirus 71,” Vaccine, vol. 29, no. 26, pp. 4362–4372, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. L. J. Reed and H. Muench, “A simple method of estimating fifty per cent endpoints,” American Journal of Epidemiology, vol. 27, no. 3, pp. 493–497, 1938. View at Scopus
  22. C. C. Liu, M. S. Guo, F. H. Y. Lin et al., “Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system,” PLoS ONE, vol. 6, no. 5, Article ID e20005, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Panezutti, O. James, E. J. Hansen et al., “Identification of surface-exposed B-cell epitopes recognized by Haemophilus influenzae type b P1-specific monoclonal antibodies,” Infection and Immunity, vol. 61, no. 5, pp. 1867–1872, 1993. View at Scopus
  24. D. G. W. Foo, S. Alonso, M. C. Phoon, N. P. Ramachandran, V. T. K. Chow, and C. L. Poh, “Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides,” Virus Research, vol. 125, no. 1, pp. 61–68, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. D. G. W. Foo, S. Alonso, V. T. K. Chow, and C. L. Poh, “Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide,” Microbes and Infection, vol. 9, no. 11, pp. 1299–1306, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. J. N. Liu, W. Wang, J. Y. Duo et al., “Combined peptides of human enterovirus 71 protect against virus infection in mice,” Vaccine, vol. 28, no. 46, pp. 7444–7451, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Roaldao, M. C. M. Mellado, L. R. Castiho, M. J. T. Corrondo, and P. M. Alves, “Virus-like particles in vaccine development,” Expert Review of Vaccines, vol. 9, pp. 1149–1176, 2010.
  28. J. F. Han, R. Y. Cao, Y. Q. Deng et al., “Antibody dependent enhancement infection of enterovirus 71 in vitro and in vivo,” Virology Journal, vol. 8, article 106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. S. M. Wang, I. C. Chen, L. Y. Su, K. J. Huang, H. Y. Lei, and C. C. Liu, “Enterovirus 71 infection of monocytes with antibody-dependent enhancement,” Clinical and Vaccine Immunology, vol. 17, no. 10, pp. 1517–1523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. E. J. Bek, K. M. Hussain, P. Phuektes et al., “Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection,” Vaccine, vol. 29, no. 29-30, pp. 4829–4838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Dong, L. Liu, H. Zhao et al., “Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys,” Vaccine, vol. 29, pp. 6269–6275, 2011. View at Publisher · View at Google Scholar · View at Scopus